LockBit 3.0 Ransomware Attack on ABL Inc.: A Critical Breach in Biopharmaceutical Cybersecurity
LockBit 3.0 Ransomware Attack on ABL Inc.
Company Profile
ABL Inc., a subsidiary of the French bioindustrial group Institut Mérieux, is a prominent player in the biopharmaceutical sector, specializing as a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO). Based in Maryland, USA, ABL Inc. boasts a revenue of $95.6 million and employs 397 individuals. The company is instrumental in the GMP manufacturing of virus-based therapies and vaccines, and supports preclinical and clinical studies with its advanced immunology and molecular laboratory assays.
Details of the Cyberattack
The LockBit 3.0 ransomware group, known for its disruptive cyber activities, has targeted ABL Inc., leading to the exfiltration of approximately 5 terabytes of sensitive data. This data includes critical information ranging from CEO and senior management documents to laboratory data and customer information. The attack has compromised over 200 different devices, highlighting a significant breach in ABL's cybersecurity measures.
Industry Standing and Vulnerabilities
The attacked company's prominence in the healthcare and biopharmaceutical industry, combined with its extensive handling of sensitive data, makes it an attractive target for cybercriminals. The nature of its operations, involving substantial data on therapies and vaccines, adds layers of risk, particularly if cybersecurity measures are not robust enough to ward off sophisticated threats like those posed by LockBit 3.0.
Sources
See Halcyon in action
Interested in getting a demo?
Fill out the form to meet with a Halcyon Anti-Ransomware Expert!